The 1998 national Belgian consensus meeting on HP-related diseases: An extensive summary

摘要: HP testing must be regarded as ONE of the important elements proper diagnostic work-up a DISEASE, managed in close cooperation between GP's and specialists: that's key message national consensus meeting held CHU Brugmann on February 6 th 7 1998. (usually by 2 direct methods: RUT-histology) eradication treatment (ER), infected patients, are strongly recommended in: 1. Past or current GDU (absolute indication), regardless activity, complication(s), NSAID intake ; 2. Low-grade MALT Lymphomas (Stage IE1) unequivocally diagnosed, followed-up specialised centers; 3. Post endoscopic resection EGC. ER is advisable carriers with family history gastric cancer. Chronic atrophic-, lymphocytic, giant folds gastritis hyperplastic polyps acceptable indications for well scheduled long-term individuals known status. Systematic HP+ patients fully investigated NUD not indicated but could considered individual patients. Extra alimentary disorders auto immune no indication there was test treat policy under 45 yrs old without alarm symptoms. screening asymptomatic ecommended. A correct monitoring after recommended, mainly UBT. In severe refractory PUD, symptom recurrence follow-up EGC Maltomas, mandatory. The first line course (except allergy intolerance) PPI full dose bid, Clarithromycin 500 mg bid Amoxycillin 1000 (7 days minimal 10 maximal). RBC-based schemes locally validated quadruple therapy proposed when retreatment needed. Culture, optional failure, second failure. Overall, therapies safe neither decreased efficacy acid-lowering drugs, nor possible increased risk peptic oesophagitis contra-indications to eradicate. cost-effective cost-beneficial PUD adjusted number pills delivered would cut costs. No clear economic data currently available potential benefit GC prevention management. resistance (Macrolides Imidazoles) organized centers.